NCT06967311 Human and Microbial Determinants of the Onset of IBD Flares
| NCT ID | NCT06967311 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Viome |
| Condition | IBD (Inflammatory Bowel Disease) |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-01-31 |
| Primary Completion | 2030-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-01-31 with a primary completion date of 2030-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will collect longitudinal biological samples and survey data to identify the triggers of IBD flares.
Eligibility Criteria
Inclusion Criteria: * Patient at Universidade Federal de Santa Catarina (UFSC) Hospital, under care of Dr. Vivian Menegassi Exclusion Criteria: * Cancer Diagnosis/Treatment * Under 18 years old
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06967311 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying IBD (Inflammatory Bowel Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06967311 currently recruiting?
Yes, NCT06967311 is actively recruiting participants. Contact the research team at studies@viome.com for enrollment information.
Where is the NCT06967311 trial being conducted?
This trial is being conducted at Florianópolis, Brazil.
Who is sponsoring the NCT06967311 clinical trial?
NCT06967311 is sponsored by Viome. The trial plans to enroll 100 participants.